FDA: Baxter Issues Voluntary Nationwide Recall of Cefazolin in Dextrose Injection, USP, 2G/100 ML Single Dose Infusion Bag

Published: 07/27/2026

Sources:
  • Food and Drug Administration
Relevant To:
  • Ambulatory Surgical Centers,
  • Rural Emergency Hospitals,
  • Urgent Care,
  • Critical Access Hospitals,
  • Hospitals,
  • Office-Based Surgery,
  • Pharmacy,
  • Rural Health Clinics

Baxter International Inc. is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter found in the solution identified as cardboard.

  • The product is used intravenously to treat bacterial infections or prevent bacterial infections during surgery.

The impacted products were distributed from March 25, 2025 through June 30, 2025.

Affected Product:

Product Code

Product Description

Sign Up for Free Trial